Translating associations between common kidney diseases and genetic variation into the clinic

Seminars in Nephrology

Volumn 30, Issue 2, 2010, Pages 195-202

  Drawz, Paul E ^a   Sedor, John R ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Clinical utility; Genetics; Nephrology; Prediction; Risk assessment

Indexed keywords

CREATININE; METFORMIN; SULFONYLUREA;

ALBUMINURIA; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; EFFECT SIZE; ETHNIC DIFFERENCE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEPATITIS C; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LINKAGE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESPONSE;

CLINICAL MEDICINE; FORECASTING; GENETIC VARIATION; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY DISEASES; NEPHROLOGY;

EID: 77950495030     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.01.010     Document Type: Article

References (50)

1. Scott L.J., Mohlke K.L., Bonnycastle L.L., et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316:1341-1345.
2. van der Net J.B., van Etten J., Yazdanpanah M., et al. Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia. Eur Heart J 2008, 29:1370-1376.
3. Frayling T.M., Timpson N.J., Weedon M.N., et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316:889-894.
4. Wang J., Ban M.R., Zou G.Y., et al. Polygenic determinants of severe hypertriglyceridemia. Hum Mol Genet 2008, 17:2894-2899.
5. Pattaro C., Aulchenko Y.S., Isaacs A., et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int 2009, 76:297-306.
6. Chen G., Adeyemo A.A., Zhou J., et al. A genome-wide search for linkage to renal function phenotypes in West Africans with type 2 diabetes. Am J Kidney Dis 2007, 49:394-400.
7. Fox C.S., Yang Q., Cupples L.A., et al. Genomewide linkage analysis to serum creatinine, GFR, and creatinine clearance in a community-based population: the Framingham Heart Study. J Am Soc Nephrol 2004, 15:2457-2461.
8. Freedman B.I., Langefeld C.D., Rich S.S., et al. A genome scan for ESRD in black families enriched for nondiabetic nephropathy. J Am Soc Nephrol 2004, 15:2719-2727.
9. Arar N.H., Voruganti V.S., Nath S.D., et al. A genome-wide search for linkage to chronic kidney disease in a community-based sample: the SAFHS. Nephrol Dial Transplant 2008, 23:3184-3191.
10. Leon J.M., Freedman B.I., Miller M.B., et al. Genome scan of glomerular filtration rate and albuminuria: the HyperGEN study. Nephrol Dial Transplant 2007, 22:763-771.
11. Ji W., Foo J.N., O'Roak B.J., et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008, 40:592-599.
12. Hirschhorn J.N. Genomewide association studies - illuminating biologic pathways. N Engl J Med 2009, 360:1699-1701.
13. Kraft P., Hunter D.J. Genetic risk prediction - are we there yet?. N Engl J Med 2009, 360:1701-1703.
14. Weedon M.N., McCarthy M.I., Hitman G., et al. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med 2006, 3:e374.
15. van Hoek M., Dehghan A., Witteman J.C., et al. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 2008, 57:3122-3128.
16. Lango H., Palmer C.N., Morris A.D., et al. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 2008, 57:3129-3135.
17. van der Net J.B., Janssens A.C., Defesche J.C., Kastelein J.J., Sijbrands E.J., Steyerberg E.W. Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia. Am J Cardiol 2009, 103:375-380.
18. Lyssenko V., Jonsson A., Almgren P., et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008, 359:2220-2232.
19. Kathiresan S., Melander O., Anevski D., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008, 358:1240-1249.
20. Goldstein D.B. Common genetic variation and human traits. N Engl J Med 2009, 360:1696-1698.
21. Riordan J.R., Rommens J.M., Kerem B., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
22. Altshuler D., Daly M.J., Lander E.S. Genetic mapping in human disease. Science 2008, 322:881-888.
23. Hardy J., Singleton A. Genomewide association studies and human disease. N Engl J Med 2009, 360:1759-1768.
24. Chakraborty R., Weiss K.M. Admixture as a tool for finding linked genes and detecting that difference from allelic association between loci. Proc Natl Acad Sci U S A 1988, 85:9119-9123.
25. Smith M.W., O'Brien S.J. Mapping by admixture linkage disequilibrium: advances, limitations and guidelines. Nat Rev Genet 2005, 6:623-632.
26. Weedon M.N., Lango H., Lindgren C.M., et al. Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet 2008, 40:575-583.
27. Manolio T.A., Collins F.S., Cox N.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
28. Cook N.R., Ridker P.M. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009, 150:795-802.
29. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. -207-12.
30. Ware J.H. The limitations of risk factors as prognostic tools. N Engl J Med 2006, 355:2615-2617.
31. Kao W.H., Klag M.J., Meoni L.A., et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40:1185-1192.
32. Arrondel C., Vodovar N., Knebelmann B., et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol 2002, 13:65-74.
33. Freedman B.I., Hicks P.J., Bostrom M.A., et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009, 75:736-745.
34. Freedman B.I., Kopp J.B., Winkler C.A., et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study. Am J Nephrol 2009, 29:626-632.
35. Kopp J.B., Smith M.W., Nelson G.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175-1184.
36. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
37. D'Agostino R.B., Grundy S., Sullivan L.M., Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.
38. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
39. Bang H., Vupputuri S., Shoham D.A., et al. SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med 2007, 167:374-381.
40. Kshirsagar A.V., Bang H., Bomback A.S., et al. A simple algorithm to predict incident kidney disease. Arch Intern Med 2008, 168:2466-2473.
41. Florez J.C., Jablonski K.A., Bayley N., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006, 355:241-250.
42. Sheppard P., Kindsvogel W., Xu W., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-68.
43. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
44. Knowler W.C., Coresh J., Elston R.C., et al. The Family Investigation of Nephropathy and Diabetes (FIND): design and methods. J Diabetes Complications 2005, 19:1-9.
45. Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999, 22:99-111. Epidemiology of Diabetes Interventions and Complications (EDIC).
46. Mueller P.W., Rogus J.J., Cleary P.A., et al. Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 2006, 17:1782-1790.
47. Jakobsdottir J., Gorin M.B., Conley Y.P., Ferrell R.E., Weeks D.E. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet 2009, 5:e1000337.
48. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
49. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004, 22:1055-1062.
50. Couzin J. Genetics. DNA test for breast cancer risk draws criticism. Science 2008, 322:357.